<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04852575</url>
  </required_header>
  <id_info>
    <org_study_id>E-1132-20</org_study_id>
    <nct_id>NCT04852575</nct_id>
  </id_info>
  <brief_title>ReVital-CORE Program</brief_title>
  <acronym>ReVital-CORE</acronym>
  <official_title>ReVital Chemotherapy Online Resiliency Evaluation (ReVital-CORE) Program Pilot Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kessler Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Select Medical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kessler Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pilot feasibility study of the ReVital Chemotherapy Online Resiliency Evaluation (CORE)&#xD;
      program. As part of standard of care, patients starting a new chemotherapy regimen are&#xD;
      referred to complete a pre-chemotherapy cancer rehabilitation evaluation (i.e., prehab) and&#xD;
      invited to enroll in the ReVital-CORE program study.&#xD;
&#xD;
      Once enrolled in ReVital-CORE, participants will complete a monthly online evaluation for 1&#xD;
      year. If frailty (or pre-frailty) is detected on any survey, physical or occupational therapy&#xD;
      will be initiated for standard of care rehabilitation evaluation and treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients starting a new chemotherapy regimen will be referred to completed a prehab&#xD;
      evaluation with a specialized physical or occupational therapist be and invited to enroll in&#xD;
      the ReVital-CORE program for the pilot, feasibility study.&#xD;
&#xD;
      Participants in the ReVital-CORE program study will be emailed an online evaluation each&#xD;
      month via for one year. Once completed, the evaluation is automatically scored into: frail,&#xD;
      pre-frail or robust categories using a validated frailty index. Any patient categorized as&#xD;
      frail or pre-frail will be re-referred to rehabilitation by their cancer care team. For frail&#xD;
      and pre-frail individuals, standard of care rehabilitation therapy will include either/and&#xD;
      occupational and physical therapy evaluation and treatment and will be billed via their&#xD;
      insurance.&#xD;
&#xD;
      The purpose of this pilot study is to evaluate feasibility of the of the ReVital-CORE Program&#xD;
      for individuals starting a new chemotherapy regimen. Secondary aims are to evaluate the&#xD;
      prevalence, trajectory and predictors of frailty during the first year of chemotherapy&#xD;
      treatment; and evaluate the impacts of prehab/rehabilitation for participants identified as&#xD;
      frail and pre-frail.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 25, 2021</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 25, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Accrual to the ReVital-CORE program.</measure>
    <time_frame>02/2022</time_frame>
    <description>Proportion of patients who consent to enroll, out of the total number invited.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of frailty at major time points.</measure>
    <time_frame>02/2023</time_frame>
    <description>Proportion of participants at all major timepoints (pre-chemo, and monthly following start of chemo for 12 months) who are identified as frail or pre-frail by a patient-reported frailty index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of therapy on global quality of life.</measure>
    <time_frame>02/2023</time_frame>
    <description>Change from baseline to discharge in quality of life as measured by the Patient Reported Outcomes Measuring System (PROMIS)-global 10-item questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of therapy on frailty.</measure>
    <time_frame>02/2023</time_frame>
    <description>Change from baseline to discharge in frailty as measured by a patient-reported frailty index.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Frailty</condition>
  <condition>Cancer</condition>
  <condition>Chemotherapy-Induced Change</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals diagnosed with cancer who are starting a new chemotherapy regimen (note: can be&#xD;
        any line of chemotherapy)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18 years or older&#xD;
&#xD;
          -  English speaking&#xD;
&#xD;
          -  Starting new chemotherapy treatment with oncology partner&#xD;
&#xD;
          -  Provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Eligible for hospice care&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Mackenzi Pergolotti, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Select Medical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kessler Institute for Rehabilitation</name>
      <address>
        <city>West Orange</city>
        <state>New Jersey</state>
        <zip>07052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 1, 2021</study_first_submitted>
  <study_first_submitted_qc>April 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2021</study_first_posted>
  <last_update_submitted>April 17, 2021</last_update_submitted>
  <last_update_submitted_qc>April 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kessler Foundation</investigator_affiliation>
    <investigator_full_name>Mackenzi Pergolotti</investigator_full_name>
    <investigator_title>Senior Director, Research and Clinical Development</investigator_title>
  </responsible_party>
  <keyword>Frailty</keyword>
  <keyword>Cancer</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Care coordination</keyword>
  <keyword>Online</keyword>
  <keyword>Prospective surveillance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Frailty</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD will not be shared with other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

